Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Boundless Bio, Inc.
Ocellaris Pharma, Inc.
Transgene
Novartis
Valo Therapeutics Oy
Numab Therapeutics AG
NextPoint Therapeutics, Inc.
Cyteir Therapeutics, Inc.
Xencor, Inc.
Innolake Biopharm
TransThera Sciences (Nanjing), Inc.
BioEclipse Therapeutics
Corvus Pharmaceuticals, Inc.
NBE-Therapeutics AG
Tempest Therapeutics
Nektar Therapeutics
Eli Lilly and Company
NKGen Biotech, Inc.
Tocagen Inc.
CytoMed Therapeutics Pte Ltd
Merrimack Pharmaceuticals
Cellectar Biosciences, Inc.